Search research articles
Contact Us
Filters
Showing results (81-90 of 96) with videos related to
Page
of 10
Sort By:
Plos Genetics
|
June 24, 2015
Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia
Sabine Topka, Joseph Vijai, Michael F Walsh, et al.
JCO Precision Oncology
|
January 15, 2026
Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis
Susanne A Gatz, Julia Glade-Bender, Andrew D J Pearson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 6, 2022
Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
Andrew Dj Pearson, Carl Allen, Jason Fangusaro, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 15, 2025
Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancer
Steven G DuBois, Lucas Moreno, Rochelle Bagatell, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 18, 2025
Paediatric strategy forum for medicinal product development of cyclin-dependent kinase inhibitors in children and adolescents ACCELERATE in collaboration with the European Medicines Agency With participation of the Food and Drug Administration
Andrew Dj Pearson, Susan Chi, Theodore W Laetscht, et al.
Nature Communications
|
February 16, 2020
MYCN amplification and ATRX mutations are incompatible in neuroblastoma
Maged Zeineldin, Sara Federico, Xiang Chen, et al.
Cancer Cell
|
August 28, 2018
Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses
Elizabeth Stewart, Justina McEvoy, Hong Wang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 27, 2024
Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer
Andrew Dj Pearson, Steven G DuBois, Margaret E Macy, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 13, 2023
Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
Andrew D J Pearson, Sara Federico, Susanne A Gatz, et al.
The Lancet. Oncology
|
April 3, 2025
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis
Andrew D J Pearson, Claudia Rossig, Crystal L Mackall, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 96) with videos related to
Sort By:
Page
of 10
Plos Genetics
|
June 24, 2015
Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia
Sabine Topka, Joseph Vijai, Michael F Walsh, et al.
JCO Precision Oncology
|
January 15, 2026
Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis
Susanne A Gatz, Julia Glade-Bender, Andrew D J Pearson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 6, 2022
Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
Andrew Dj Pearson, Carl Allen, Jason Fangusaro, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 15, 2025
Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancer
Steven G DuBois, Lucas Moreno, Rochelle Bagatell, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 18, 2025
Paediatric strategy forum for medicinal product development of cyclin-dependent kinase inhibitors in children and adolescents ACCELERATE in collaboration with the European Medicines Agency With participation of the Food and Drug Administration
Andrew Dj Pearson, Susan Chi, Theodore W Laetscht, et al.
Nature Communications
|
February 16, 2020
MYCN amplification and ATRX mutations are incompatible in neuroblastoma
Maged Zeineldin, Sara Federico, Xiang Chen, et al.
Cancer Cell
|
August 28, 2018
Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses
Elizabeth Stewart, Justina McEvoy, Hong Wang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 27, 2024
Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer
Andrew Dj Pearson, Steven G DuBois, Margaret E Macy, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 13, 2023
Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
Andrew D J Pearson, Sara Federico, Susanne A Gatz, et al.
The Lancet. Oncology
|
April 3, 2025
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis
Andrew D J Pearson, Claudia Rossig, Crystal L Mackall, et al.
Page
of 10